Proton and Neutron Beam Therapies
Customize your policy alerts
Sign up for mhn Policy CP.MP.70 alerts
Get alerted when Policy CP.MP.70 changes without checking for updates manually.
Monitor payer policy activity
Defines medical necessity criteria and guidance for coverage of proton beam therapy (PBT) and neutron beam therapy (NBT) for members/enrollees of Centene-affiliated health plans; intended for clinicians and prior authorization reviewers.
No material clinical or coverage changes in this revision.
Coverage Criteria for Proton and Neutron Beam Therapies
inv-02: NBT medical necessity indications
Neutron beam therapy (NBT) is medically necessary for salivary gland tumors when ANY of the following are met:
NBT coverage limited to these salivary gland tumor scenarios.
inv-03: Policy criteria and historical additions
Policy includes a comprehensive set of criteria (I.A through I.W and II) for indications where proton and/or neutron therapy may be considered medically necessary; numerous additions and refinements were made across annual reviews.
This node summarizes revisions to criteria across documented annual reviews and clarifications.
inv-04: Neutron Beam Therapy clinical stance
Clinical stance regarding Neutron Beam Therapy (NBT).
Derived from NCCN position and clinical context.
All other indications for proton beam therapy (PBT) and neutron beam therapy (NBT) that are not explicitly listed in this policy are considered not medically necessary. The policy states that insufficient evidence exists to recommend PBT and/or NBT as superior to other available treatments outside of the enumerated indications, and such requests would be denied when not meeting the specific covered criteria.
The NCCN commentary referenced in this policy indicates that neutron beam therapy (NBT) was historically considered promising for unresectable salivary gland cancers but is no longer recommended as a general solution. Reasons cited include diminishing demand, high rates of long-term toxicity, concerns about the methodological robustness of randomized trial data, and the closure of nearly all U.S. treatment centers; NCCN acknowledges NBT may still have potential value for select patients.
Any request for PBT or NBT that does not meet one of the policy’s enumerated indications is considered not medically necessary. Approval is limited to the specific clinical scenarios listed in the policy; uses outside those scenarios should be treated as non-covered absent additional supporting evidence.
Inclusion of CPT codes or other procedure codes in this clinical policy is for informational purposes only and does not guarantee coverage. The absence of explicit coverage language for a particular clinical presentation in this excerpt should not be interpreted as medical necessity; providers must verify plan-specific coding and coverage guidance prior to claim submission.
Procedure and Billing Codes
| CPT referenced (no specific codes listed in this part) | Policy references CPT codes and descriptions for informational purposes; no explicit CPT codes provided in this document section. |
| 77423 | High energy neutron radiation treatment delivery, 1 or more isocenter(s) with coplanar or non-coplanar geometry with blocking and/or wedge, and/or compensator(s). |
| 77520 | Proton treatment delivery; simple, without compensation. |
| 77522 | Proton treatment delivery; simple, with compensation. |
| 77523 | Proton treatment delivery; intermediate. |
| 77525 | Proton treatment delivery; complex. |
| S8030 | Scleral application of tantalum ring(s) for localization of lesions for proton beam therapy. |
Provider Requirements and Authorization
Prior Authorization Required
Prior authorization is required for requests for proton beam therapy (PBT) and neutron beam therapy (NBT). Approval is limited to the medically necessary indications listed in this policy. Providers should follow Health Plan procedures to obtain prior authorization and verify any plan‑specific requirements before scheduling treatment.
- Prior authorization required for PBT and NBT for covered indications only
- Approval limited to listed medically necessary indications; requests for other indications are likely to be denied
Preference for Photon Therapy When Constraints Met
Photon (x‑ray) therapy is the preferred modality when normal tissue and organ‑at‑risk dose constraints can be met. Proton therapy should be reserved for cases in which photon‑based techniques would exceed organ‑at‑risk constraints or where a proton‑based technique lowers the probability of clinically meaningful normal tissue toxicity.
- Photon therapy preferred when normal tissue constraints can be satisfied
- PBT indicated when photon therapy would exceed critical organ dose constraints
Required Clinical and Coding Documentation
Providers must submit clinical documentation to support the medical necessity of PBT/NBT. Required documentation includes tumor localization and treatment‑planning information (for example: imaging reports such as MRI/CT, operative reports, pathology, documentation of fiducial placement when applicable, and radiation treatment planning details demonstrating organ‑at‑risk doses and comparisons to photon plans).
- Imaging and tumor localization (MRI, CT, ultrasound, ophthalmoscopy where applicable)
- Operative and pathology reports when relevant
- Documentation of fiducials or localization technique for ocular tumors
- Radiation treatment planning details, including organ‑at‑risk dose constraints and comparison to photon plans
Step Therapy
In some instances, step therapy may be relevant when alternative, clinically appropriate radiation modalities exist; however, this policy does not specify explicit step therapy requirements. Providers should confirm any plan‑level step therapy or utilization management protocols that may apply.
- No explicit step therapy requirements specified in this policy
- Verify plan‑specific step therapy or utilization management rules
Coding Does Not Guarantee Coverage
Inclusion of procedure or diagnosis codes in this policy is for informational purposes only and does not guarantee coverage. Providers must reference the most current coding guidance and verify benefit, coverage, and claim submission requirements with the member's Health Plan prior to billing.
- Coding references are informational only; inclusion or exclusion does not ensure coverage
- Verify up‑to‑date coding guidance and plan benefit coverage before claim submission
Background and Rationale
Proton beam therapy (PBT) is an external beam radiation modality that uses protons to deliver dose with a distinct depth-dose profile, characterized by limited exit dose beyond the target. This physical property allows for greater sparing of surrounding normal tissues and critical structures compared with conventional photon therapy, which can be particularly beneficial for well-demarcated tumors, pediatric patients, and situations where photon-based approaches cannot meet organ-at-risk constraints. PBT is therefore used clinically when its depth-dose characteristics enable dose escalation or organ preservation that would not be achievable with photons.
Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.